ASCO GU 2024

BRCAAway - practice changing or hypothesis generating…

Cabo + IO: Interesting but not practice changing?!

Combination vs. monotherapy - a great new option for…

Relugolix combined with androgen signaling in real word…

Combination NHT + PARP makes sense

Gleason 3+3 - cancer or not?

Cognitive function in ART treatment

Dose de-escalation in different ways

Enzalutamide therapy as option for biochemical…

Insights and news for mCRPC

Still a difficult time for androgenic inhibitors in…

What about the clinical benefit?

Therapy Intensification Still Neglected in mHSPC

First positive study of IO therapy in mCRPC

Stockholm3 validated in multiethnic cohort

Localized PCa - news for radiotherapy and biochemical…

Evaluating the recombination-repair mutations in…

Combination of cabozantinib & checkpoint inhibitor

BRCAaway - PARP combination study

Higher radiation is effective in high-risk PCA

Quality of life under intensive therapy

Long-term dose escalation - Therapy in high-risk…

Olaparib + Arbiraterone better compared to either alone

Further testing before olaparib combination

Kombination av cabozantinib och immunterapi

Une période encore difficile pour les inhibiteurs…

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

SEPTA calismasi: Stockholm3 un multietnik hasta…

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

Gleason 3+3 ska vi kalla de cancer eller inte?

Post-RP salvage radyoterapi hormonoterapi ile konbine…

Kognitiv påverkan av abirateron och enzalutamid?

BRCAAway - PARP hämmare, abiraterone eller i…

ADC + ICI: new data for platinum-refractory bladder…

New standard of care, but still open questions!

The emerging field of biomarkers in bladder cancer

HER2 and bladder cancer

EV as standard in 3rd line mUC

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Should we start forgetting the Galsky Criteria in…

Adjuvant therapy in urothelial carcinoma : is the…

ASCO GU24 - Highlights in Bladder cancer

Highlights in bladder cancer at ASCO GU24

Perioperative adjuvant therapy in urothelial cancer

Update M1 urothelial cancer

Another success for an ICI?

MIBC: adjuvant PD1 - all set?!

EV + Pembro new first-line standard in localized…

Biomarker update

Update on EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de…

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Novedades sobre EV-302

Tratamiento adyuvante en cancer urotelial: ¿está…

Terapia adyuvante perioperatoria en el cáncer de vejiga

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Trial updates at ASCO GU24: Are the follow-up data…

Subcutaneous vs. intravenous application: ready for…

Overall survival benefit - Pembro after surgery

Cabozantinib Plus Atezolizumab in Adrenocortical…

Practice changing adjuvant therapy?!

Durable effects of Ipi-Nivo

Highlights in kidney cancer at ASCO GU24

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Long-Term Data on NIVO+IPI in aRCC

ASCO GU24 - Highlights in renal cell carcinoma

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Long-term follow-up of first-line trials

Long-term outcome

Belzutifan: Updates on QoL

Better QoL with Belzutifan

Tumorburden and outcome

Tratamiento perioperatorio en cancer renal: ¿Hemos…